Set-Up↦Monitoring↦Site Initation Visit↦Conduct
Was betrifft es? Warum ist das wichtig?
During the Site Initiation Visit (SIV), participating study sites are made ready for study conduct, which includes the important training of study staff.
Depending whether it is a mono- or multicentre study, the SIV can be performed as:
- A personal visit to the site
- A video conference
- A telephone conference
The type of visit to choose depends on:
- Study complexity (e.g. study design) and study risk (e.g. risk-benefit-ratio), as determined by the RBM score calculator
- The distance between SP-INV location and study site, and thus expected cost
The SIV is documented in:
- The SIV report
- The monitoring visit log, which is signed by the monitor and a site staff member
- The site staff attendance-log
If practicable, a SIV can be planned as a joint meeting, where several different sites from the same study participate.
Mehr
During SIV, there are several different issues that must be trained and discussed with the site staff:
- The study protocol (e.g. study design, eligibility criteria, study outcome / endpoint)
- An overview and location of study SD
- Staff responsibilities (e.g. introduction of a site delegation log). Even though the Site-INV can delegate study tasks to qualified site staff, the final responsibility always remains with the Site-INV
- Safety reporting procedures
- The handling of the Investigational Medicinal Product (IMP) or Investigational Medical Device (IMD) (e.g. labelling, storage conditions, access rights, inventory, preparation/assembly, dispensing to study participants)
- The introduction of special procedures (e.g. diagnostic tests, IMP/MD preparation and application, computer programs)
- Processes that are solely performed at study site (e.g. IMP/IMD handling, laboratory procedures, database access)
- CRF entries (e.g. login, introduction of a study ID for participants)
- Study documentation (e.g. management of study documents, TMF/ISF maintenance, training documentation)
- Compliance with the study protocol and as applicable with GCP, the Swiss laws and regulations (e.g. Declaration of Helsinki, ISO 14155, ISO 20916, ISO 20387). Any substantial protocol amendment can only be implemented after initial Ethics Committee (EC) and RA (e.g. Swissmedic) approval, as applicable
- Communication lines with the SP-INV
- The purpose of monitoring and the monitoring duties of the Site-INV (e.g. provide all necessary documents including medical record needed by the monitor during monitoring visits)
Was muss ich befolgen?
As a monitor ensure that the Site-INV and relevant study staff have adequate time at their disposal and are present during the SIV.
If you are the study monitor:
- Follow activities as stated in the agenda and remain within timelines
- Allow time for questions and answers
- Ensure that attendees date and sign
- The study delegation-log
- The SIV attendance-log
- Check and finalise TMF/ISF filing
- Define procedures for potential outstanding issues / findings, including timelines and follow-up
After the monitoring visit, the monitor:
- Generates a list of all unresolved issues with suggestions on how to resolve them
- Creates a timeline with deadlines for any outstanding issues. In the event of:
- Minor issues, the site may proceed with participant recruitment (e.g. pre-screening) but must resolve issues within a defined timeline
- Major issues, the site must resolve issues prior to recruitment
- Is responsible to follow-up on any outstanding issues identified during SIV, in order to ensure site compliance
Mehr
Discusses with the SP-INV whether to postpone participant recruitment due to major unresolved issues that might negatively affect participant safety or the quality of study data.
Major issues could be:
- Screening tools and material required for participant recruitment are incomplete or missing (e.g. laboratory kits)
- The investigational product (IMP / IMD) has not yet been delivered to the study site
- Staff has no access to eCRF which is needed to enter any collected study data into the study database
- Required staff trainings are still outstanding (e.g. data entry into the study database, handling of the investigational product)
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- Glossary: definition monitoring
- 3.10.1.3 Risk control
- 3.11.4 Monitoring
- 3.11.4.3 Monitoring plan
- 3.11.4.4 Monitoring procedures
- 3.11.4.5 Monitoring activities
- 3.11.4.5.1 Communication with parties conducting the trial
- 3.11.4.5.3 Monitoring of Investigational Product Management
- Appendix C. Essential documents for the conduct of a clinical trial
ISO 14155 Medical Device – see in particular section (access liable to costs)
- 9.2.4.4 Initiation of the investigation site
- Annex E: Essential clinical investigation documents
Swiss Law
ClinO – see in particular article
- Art. 5 Good Clinical Practice